Skip to content

Startup & venture capital news

Celaid Therapeutics adds JPY 400m in Series B second close

The new tranche supports stem-cell therapy development

By /

LinkedInX
Celaid Therapeutics: Celaid Therapeutics adds JPY 400m in Series B second close

Celaid Therapeutics announced an additional JPY 400 million in the second close of its Series B. The release appeared on 5 October 2026 in Amsterdam time, following publication late on 4 October in US Eastern time. Shionogi and Teikoku Ventures are named investors, with no lead explicitly stated. The Tokyo company develops stem-cell therapies for severe diseases, with the financing supporting development and preparations for clinical studies in the United States. The amount refers to the incremental second close, rather than the entire Series B total. Celaid's investment story combines a therapeutic programme with capital supporting its next development stages.

Keep reading

More Funding

All stories